Core Laboratories (NYSE:CLB) – Stock analysts at Piper Jaffray Companies reduced their FY2018 earnings per share estimates for Core Laboratories in a research report issued on Thursday, October 25th. Piper Jaffray Companies analyst I. Macpherson now anticipates that the oil and gas company will post earnings per share of $2.15 for the year, down from their previous estimate of $2.37. Piper Jaffray Companies has a “Hold” rating and a $87.00 price target on the stock. Piper Jaffray Companies also issued estimates for Core Laboratories’ Q4 2018 earnings at $0.50 EPS, Q1 2019 earnings at $0.48 EPS, Q2 2019 earnings at $0.51 EPS, Q3 2019 earnings at $0.64 EPS, Q4 2019 earnings at $0.71 EPS and FY2020 earnings at $3.35 EPS.
Core Laboratories (NYSE:CLB) last released its quarterly earnings data on Wednesday, October 24th. The oil and gas company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. Core Laboratories had a net margin of 13.21% and a return on equity of 68.00%. The business had revenue of $182.15 million for the quarter, compared to analysts’ expectations of $178.11 million. During the same quarter last year, the company earned $0.46 EPS. The company’s revenue for the quarter was up 11.8% compared to the same quarter last year.
CLB stock opened at $84.02 on Monday. The company has a debt-to-equity ratio of 1.83, a quick ratio of 1.85 and a current ratio of 2.31. Core Laboratories has a fifty-two week low of $83.15 and a fifty-two week high of $130.34. The stock has a market capitalization of $3.85 billion, a P/E ratio of 42.01, a PEG ratio of 2.41 and a beta of 1.46.
A number of institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its position in shares of Core Laboratories by 3.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 277,192 shares of the oil and gas company’s stock valued at $29,998,000 after purchasing an additional 8,287 shares in the last quarter. UBS Group AG boosted its position in shares of Core Laboratories by 32.6% during the 1st quarter. UBS Group AG now owns 18,842 shares of the oil and gas company’s stock valued at $2,039,000 after purchasing an additional 4,629 shares in the last quarter. A.R.T. Advisors LLC bought a new position in shares of Core Laboratories during the 1st quarter valued at about $595,000. LPL Financial LLC boosted its position in shares of Core Laboratories by 35.5% during the 1st quarter. LPL Financial LLC now owns 2,950 shares of the oil and gas company’s stock valued at $319,000 after purchasing an additional 773 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its position in shares of Core Laboratories by 41.1% during the 1st quarter. Guggenheim Capital LLC now owns 16,190 shares of the oil and gas company’s stock valued at $1,751,000 after purchasing an additional 4,718 shares in the last quarter.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 20th. Shareholders of record on Friday, October 19th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Thursday, October 18th. This represents a $2.20 annualized dividend and a yield of 2.62%. Core Laboratories’s payout ratio is 110.00%.
About Core Laboratories
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Featured Story: Should I invest in “strong buy” stocks?
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.